BDTXBlack Diamond Therapeutics,...

Nasdaq blackdiamondtherapeutics.com


$ 4.85 $ -0.37 (-7.06 %)    

Friday, 17-May-2024 15:59:55 EDT
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 4.87
$ 5.24
$ 4.85 x 391
$ 4.88 x 400
$ 4.85 - $ 5.28
$ 1.57 - $ 7.66
1,243,531
na
252.31M
$ 1.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-12-2024 12-31-2023 10-K
3 11-06-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-09-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-07-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-24-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-black-diamond-therapeutic-lowers-price-target-to-11

HC Wainwright & Co. analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and lowers the pri...

 black-diamond-therapeutic-q1-2024-gaap-eps-035-beats-044-estimate

Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimat...

 wedbush-maintains-outperform-on-black-diamond-therapeutic-raises-price-target-to-16

Wedbush analyst Robert Driscoll maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and raises the price tar...

 black-diamond-therapeutics-presented	novel-real-world-evidence-of-the-evolving-egfr-mutation-landscape-in-nsclc-and-the-opportunity-for-bdtx-1535-in-an-oral-presentation-at-the-2024-aacr-annual-meeting

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data sho...

 hc-wainwright--co-reiterates-buy-on-black-diamond-therapeutic-raises-price-target-to-12

HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the pr...

 wedbush-reiterates-outperform-on-black-diamond-therapeutic-maintains-10-price-target

Wedbush analyst Robert Driscoll reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and maintains $10 price...

 black-diamond-therapeutic-q4-eps-034-beats-047-estimate-cash-cash-equivalents-and-investments-of-1314m-expected-to-be-sufficient-to-fund-operations-into-q2-of-2025

Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimat...

 hc-wainwright--co-reiterates-buy-on-black-diamond-therapeutic-maintains-11-price-target

HC Wainwright & Co. analyst Robert Burns reiterates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and maintains $11...

 black-diamond-therapeutic-q3-eps-045-beats-046-estimate-cash-cash-equivalents-and-investments-of-1443m-expected-to-be-sufficient-to-fund-operations-into-1h-of-2025

Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimat...

 black-diamond-therapeutics-and-2-other-stocks-under-3-insiders-are-buying

The Dow Jones closed lower by around 250 points on Thursday. When insiders purchase or sell shares, it indicates their confiden...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION